Glencore boost for COVID-19 vaccine development
UQ’s ‘Molecular Clamp’ project uses technology that ensures the vaccine induces an immune response that recognises and then neutralises the virus.
On July 13 it was announced that a Phase l clinical trial involving 120 healthy adult volunteers has begun with the first dose of the UQ COVID-19 vaccine being given at the Brisbane clinic of clinical trials specialist, Nucleus Network.
Glencore’s funding comes from the company’s Community Support Fund, set up earlier this year to assist communities affected by the COVID-19 pandemic.
“Philanthropy has played a critical role in our efforts to fast-track an effective vaccine and help save lives across the world,” Professor Paul Young, co-lead of UQ’s vaccine project, said.
“With the support of Glencore, government partners and a community of almost 2,600 donors, we have been able to combine clinical readiness with scale-up manufacturing, reducing the timeframe to a vaccine by up to six months.”
In 2019, Glencore contributed more than $6.4 billion to Queensland’s economy, providing employment for about 9,230 people across its coal, copper and zinc mining operations.
IMAGE: UQ's COVID-19 vaccine candidate is administered at the Brisbane clinic of phase 1 clinical trials specialist, Nucleus Network.
Townsville will host a one-and-a-half-day conference in March focusing on injury prevention, work health and safety, rehabilitation and return to work...